Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced plans to launch a new web portal on ms360.myriad.com that will allow patients to access their personal test results as well as other high-quality tools and ideas to help them make healthcare decisions.

"Nothing is more important to us than empowering and improving people's lives," said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic Laboratories. "Myriad has a long track record of providing patients with free access to their test reports directly or through their healthcare providers. The new portal will address the growing needs of patients to access information digitally."

Myriad anticipates that the first phase of the portal will be available by the end of the quarter. Initially, the site will provide access to test results for the Company's hereditary cancer and prostate cancer tests, and its functionality will expand over time in a stepwise approach to better serve patients' needs. For example, it is anticipated that it will include resources such as the Family History Tool (FHT), used to track family health history and identify red flags; flexibility to combine personal and family health histories; and the ability to print test results or email them to a healthcare provider; and more.

"Patients' interests are at the very heart of this initiative and every decision we make. We want to partner with patients and help keep them and their loved ones healthy," said Lancaster. "The new portal will provide useful resources both for patients who are currently managing a disease and their family members."

This initiative is another step toward the ultimate goal of developing broader digital assets to help patients become active participants in managing their health. On May 11, Myriad launched a new web-based portal called myVectra for patients with rheumatoid arthritis. myVectra provides patients with easy access to their Vectra DA test results and test history, which can help them to prepare for visits with their rheumatologist. The new portal is available at: my.vectrada.com.

About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G

Subscribe to Directory
Write an Article

Recent News

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un estudio de INCLIVA muestra el efecto ...

by INCLIVA

Han desarrollado un estudio para evaluar la correlación entre el teji...

Photos Stream